US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. More Details
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has US-China Biomedical Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UCBB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UCBB underperformed the US Healthcare industry which returned 17.8% over the past year.
Return vs Market: UCBB underperformed the US Market which returned 12.9% over the past year.
Price Volatility Vs. Market
How volatile is US-China Biomedical Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is US-China Biomedical Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UCBB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UCBB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UCBB is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: UCBB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UCBB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UCBB is overvalued based on its PB Ratio (5.7x) compared to the US Healthcare industry average (2.8x).
How is US-China Biomedical Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as US-China Biomedical Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of UCBB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access US-China Biomedical Technology's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
How has US-China Biomedical Technology performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: UCBB is currently unprofitable.
Growing Profit Margin: UCBB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if UCBB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare UCBB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UCBB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: UCBB has a negative Return on Equity (-599.74%), as it is currently unprofitable.
How is US-China Biomedical Technology's financial position?
Financial Position Analysis
Short Term Liabilities: UCBB's short term assets ($155.0K) do not cover its short term liabilities ($254.2K).
Long Term Liabilities: UCBB's short term assets ($155.0K) exceed its long term liabilities ($140.4K).
Debt to Equity History and Analysis
Debt Level: UCBB is debt free.
Reducing Debt: UCBB currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if UCBB has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if UCBB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is US-China Biomedical Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UCBB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UCBB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UCBB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UCBB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UCBB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sunny Huang (47 yo)
Mr. Qingxi Huang, also known as Sunny, has been Chief Executive Officer, Chief Financial Officer, President, Secretary and Treasurer of US-China Biomedical Technology, Inc. (formerly known as Cloud Securit ...
|Chairman||2.83yrs||no data||no data|
|Co-Founder||21.67yrs||no data||no data|
|Co-Founder||21.67yrs||no data||no data|
Experienced Management: UCBB's management team is seasoned and experienced (21.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
US-China Biomedical Technology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: US-China Biomedical Technology, Inc.
- Ticker: UCBB
- Exchange: OTCPK
- Founded: 2010
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$531.092k
- Shares outstanding: 19.82m
- Website: https://www.ucbb.us
Number of Employees
- US-China Biomedical Technology, Inc.
- 2 Park Plaza
- Suite 400
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UCBB||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||May 2012|
US-China Biomedical Technology, Inc. operates as an early stage biomedical technology and services company. The company was formerly known as Cloud Security Corporation and changed its name to US-China Bio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/22 06:38|
|End of Day Share Price||2020/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.